Disc Medicine Inc.
IRONHeld by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase3 readout (Placebo): Sep 2026. Short interest: 22.3% of float.
Held by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase3 readout (Placebo): Sep 2026. Short interest: 22.3% of float.
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.